Endpoint Enabling Study in Cyclin-dependent kinase-like 5 Deficiency Disorder (CDD)

Summary

The study is designed to identify the best outcome measures in assessing their suitability and the adaptability across a variety of countries and languages for future international clinical
trials for patients with CDD.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 0 to 17

Inclusion criteria:

Patients ages newborn to 17 years old with documented diagnosis of CDKL5 deficiency

Exclusion criteria:

Any condition that, in the opinion of the investigator, would put the patient at
undue risk or make it unsafe for the patient to participate

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

Dr. Julia Jacobs-LeVan at 4039552480 or Julia.Jacobs-LeVan@albertahealthservices.ca

Principal investigator:

Julia Jacobs-Levan

Clinical trial:

Yes

REB-ID:

REB22-0797